PMID- 18509637
OWN - NLM
STAT- MEDLINE
DCOM- 20081027
LR  - 20211020
IS  - 1619-7070 (Print)
IS  - 1619-7089 (Electronic)
IS  - 1619-7070 (Linking)
VI  - 35
IP  - 8
DP  - 2008 Aug
TI  - FDG uptake, a surrogate of tumour hypoxia?
PG  - 1544-9
LID - 10.1007/s00259-008-0758-5 [doi]
AB  - INTRODUCTION: Tumour hyperglycolysis is driven by activation of hypoxia-inducible 
      factor-1 (HIF-1) through tumour hypoxia. Accordingly, the degree of 
      2-fluro-2-deoxy-D: -glucose (FDG) uptake by tumours might indirectly reflect the 
      level of hypoxia, obviating the need for more specific radiopharmaceuticals for 
      hypoxia imaging. DISCUSSION: In this paper, available data on the relationship 
      between hypoxia and FDG uptake by tumour tissue in vitro and in vivo are 
      reviewed. In pre-clinical in vitro studies, acute hypoxia was consistently shown 
      to increase FDG uptake by normal and tumour cells within a couple of hours after 
      onset with mobilisation or modification of glucose transporters optimising 
      glucose uptake, followed by a delayed response with increased rates of 
      transcription of GLUT mRNA. In pre-clinical imaging studies on chronic hypoxia 
      that compared FDG uptake by tumours grown in rat or mice to uptake by FMISO, the 
      pattern of normoxic and hypoxic regions within the human tumour xenografts, as 
      imaged by FMISO, largely correlated with glucose metabolism although minor 
      locoregional differences could not be excluded. In the clinical setting, data are 
      limited and discordant. CONCLUSION: Further evaluation of FDG uptake by various 
      tumour types in relation to intrinsic and bioreductive markers of hypoxia and 
      response to radiotherapy or hypoxia-dependent drugs is needed to fully assess its 
      application as a marker of hypoxia in the clinical setting.
FAU - Dierckx, Rudi Andre
AU  - Dierckx RA
AD  - Department of Nuclear Medicine and Molecular Imaging, University Medical Center 
      Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands. 
      r.a.dierckx@ngmb.umcg.nl
FAU - Van de Wiele, Christophe
AU  - Van de Wiele C
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20080529
PL  - Germany
TA  - Eur J Nucl Med Mol Imaging
JT  - European journal of nuclear medicine and molecular imaging
JID - 101140988
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Cell Hypoxia
MH  - Fluorodeoxyglucose F18/*pharmacokinetics
MH  - Humans
MH  - Neoplasms/*diagnostic imaging/*metabolism
MH  - Oxygen/*metabolism
MH  - Radionuclide Imaging
MH  - Radiopharmaceuticals/pharmacokinetics
PMC - PMC2491423
EDAT- 2008/05/30 09:00
MHDA- 2008/10/28 09:00
PMCR- 2008/05/29
CRDT- 2008/05/30 09:00
PHST- 2007/10/23 00:00 [received]
PHST- 2008/02/18 00:00 [accepted]
PHST- 2008/05/30 09:00 [pubmed]
PHST- 2008/10/28 09:00 [medline]
PHST- 2008/05/30 09:00 [entrez]
PHST- 2008/05/29 00:00 [pmc-release]
AID - 758 [pii]
AID - 10.1007/s00259-008-0758-5 [doi]
PST - ppublish
SO  - Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1544-9. doi: 
      10.1007/s00259-008-0758-5. Epub 2008 May 29.